ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0393

Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis

Aditi Shaily1, Allison R. Eckard2, Paul Nietert3, Emily Vara1, Natasha Ruth4 and Mileka Gilbert3, 1Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 2Departments of InternDivision of Infectious Diseases, Medical University of South Carolina, Charleston, SC, 3Medical University of South Carolina, Charleston, SC, 4Medical University South Carolina, Charleston, SC

Meeting: ACR Convergence 2025

Keywords: Access to care, Demographics, Juvenile idiopathic arthritis, Patient reported outcomes, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Medications used to manage juvenile idiopathic arthritis (JIA) are highly effective in preventing joint damage and provide a favorable prognosis. Many patients, however, struggle with treatment adherence. Yet, little data exist on self-reported medication barriers and how they may affect treatment adherence and disease activity in this vulnerable population.

Methods: Retrospective cross-sectional analysis was used to examine medication barriers in a cohort of patients with JIA seen in an ambulatory rheumatology clinic at a quaternary care academic institution in Charleston, SC. Pediatric Rheumatology Care and Outcomes Improvement Network Barriers Assessment Tool (BAT) was used to obtain patient/caregiver-reported medication barriers. Treatment adherence rates were estimated using a patient/caregiver-driven survey. 10-point clinical Juvenile Arthritis Disease Activity Score (cJADAS-10) assessed disease activity. Primary objectives were to investigate relationships among medication barriers, medication adherence, and disease activity. Secondary objective was to evaluate for health disparities associated with medication barriers. Fisher’s exact or Wilcoxon rank-sum tests were used to make between-group comparisons.

Results: 90 patients were included (median age 14 years; 73.3% female); 75.6% reported taking ≥1 JIA medication. 36 of 90 patients (40%) reported the presence of at least one medication barrier; 54 (60%) reported not having any barriers. “Treatment is painful,” “treatment makes me uncomfortable or upset,” and “I do not like the side effects of the treatment” were the most reported barriers. Comparison groups were based on the selection of one or more medication barriers from the BAT in primary analysis; and on the response to the survey question “Do you have any barriers to, challenges with, or concerns about taking your medication(s)?” in secondary analysis. Associations between medication barriers and medication adherence rates, disease activity and sociodemographic variables were not statistically significant in the primary analysis (Tables 1 & 2). However, medication barriers were found to decrease adherence rates in the secondary analysis with a different operational definition of medication barriers (Table 3).

Conclusion: No differences were observed in treatment adherence rates, disease activity and sociodemographic factors in patients reporting medication barriers versus not reporting any barriers. However, medication adherence varied with different operational definitions of medication barriers. Hence, additional investigation is warranted to further delineate perceived medication barriers and their effects on long-term disease outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Shaily: None; A. Eckard: None; P. Nietert: None; E. Vara: None; N. Ruth: None; M. Gilbert: None.

To cite this abstract in AMA style:

Shaily A, Eckard A, Nietert P, Vara E, Ruth N, Gilbert M. Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effects-of-self-reported-medication-barriers-on-medication-adherence-and-disease-activity-in-a-cohort-of-patients-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-self-reported-medication-barriers-on-medication-adherence-and-disease-activity-in-a-cohort-of-patients-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology